ClinicalTrials.gg
Not yet recruitingNCT07503600Updated Mar 31, 2026

The Effect of Adjunctive Melatonin With Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections

A Phase 3 interventional study of Melatonin and Placebo in Multidrug-Resistant Gram-Negative Bacterial Infections and Antimicrobial Resistance, sponsored by Ain Shams University. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Ain Shams University · Phase 3, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study evaluates whether adding melatonin to standard colistin therapy improves outcomes in patients with multidrug-resistant (MDR) Gram-negative bacterial infections. These infections are difficult to treat and are associated with high morbidity and mortality, particularly in critically ill patients.

Colistin is often used as a last-line antibiotic for these infections; however, its effectiveness may be limited, and it is associated with side effects such as kidney injury. Melatonin, a naturally occurring hormone, has antioxidant, anti-inflammatory, and immune-modulating properties that may enhance the effectiveness of antibiotics and reduce treatment-related complications.

In this randomized, double-blind, placebo-controlled study, adult patients receiving colistin will be assigned to receive either melatonin or a placebo in addition to standard care. The study will assess whether melatonin improves oxidative stress, infection control, and clinical outcomes while maintaining safety.

Read the detailed description

Antimicrobial resistance is a major global health challenge, particularly among Gram-negative bacteria, which have developed resistance to multiple antibiotic classes, including last-line agents such as colistin. These infections are especially prevalent in intensive care units and are associated with poor clinical outcomes.

Given the limited development of new antibiotics, alternative strategies such as the use of adjunctive therapies are being explored. Melatonin (N-acetyl-5-methoxytryptamine) is an endogenous hormone known for its role in circadian rhythm regulation, but it also exhibits antioxidant, anti-inflammatory, and immunomodulatory effects. Emerging experimental evidence suggests that melatonin may enhance antibiotic activity and help overcome resistance mechanisms, including those affecting colistin.

This study is a prospective, randomized, double-blind, placebo-controlled clinical trial conducted in adult patients with confirmed MDR Gram-negative bacterial infections requiring intravenous colistin therapy in the intensive care setting.

Participants will be randomly assigned in a 1:1 ratio to receive either oral melatonin (60 mg once daily) or a matching placebo, initiated concurrently with colistin therapy. All patients will receive standard antimicrobial treatment and supportive care according to institutional protocols.

The primary objective is to evaluate the effect of adjunctive melatonin on oxidative stress, measured by changes in serum malondialdehyde (MDA) levels. Secondary objectives include assessment of microbiological eradication, clinical response, inflammatory markers, renal safety (including the incidence of acute kidney injury), and overall clinical outcomes such as length of stay.

This study aims to determine whether melatonin can serve as a safe and effective adjunctive therapy to improve outcomes and potentially restore the efficacy of colistin in the treatment of multidrug-resistant Gram-negative infections.

02

Conditions studied

  • Multidrug-Resistant Gram-Negative Bacterial Infections
  • Antimicrobial Resistance

Keywords

  • Gram-Negative Infections
  • multidrug resistance
  • colistin
  • gram negative infections
03

In context

Gram-Negative Bacterial Infections

59 studies on the registry are indexed under Gram-Negative Bacterial Infections; 11 are open to participants now.

This study's planned enrollment of 70 is close to the median of 70 across 43 interventional studies indexed under Gram-Negative Bacterial Infections.

Browse Gram-Negative Bacterial Infections studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Confirmed diagnosis of infection caused by multidrug-resistant Gram-negative bacteria based on microbiological culture and sensitivity testing

      • Patients receiving intravenous colistin therapy according to institutional protocols
      • Clinical diagnosis of sepsis or severe infection in accordance with established critical care criteria

Exclusion criteria

Exclusion Criteria:

    • Pregnancy or lactation

      • Terminal medical or surgical illness (e.g., advanced )
      • Severe chronic liver disease or end-stage renal failure
      • Impaired cognitive function or active psychiatric illness under treatment
      • Known to melatonin
      • Use of melatonin within 48 hours prior to enrollment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    melatonin

    Patients will receive oral melatonin 60 mg once daily, initiated concurrently with the administration of the colistin loading dose

    Drug: Melatonin

  • Placebo comparator
    Placebo

    Patients will receive matching placebo capsules following the same dosing schedule.

    Other: Placebo

Interventions

  • Patients will receive oral melatonin 60 mg once daily, initiated concurrently with the administration of the colistin loading dose

  • OtherPlacebo

    Patients will receive matching placebo capsules following the same dosing schedule.

06

What researchers measure

Primary outcomes

  1. Oxidative stress marker

    serum malondialdehyde (MDA) levels

    Time frame: day 7

Secondary outcomes

  1. microbiological eradication

    Clearance of the baseline MDR Gram-negative pathogen, confirmed by negative follow-up culture

    Time frame: Day 7

  2. inflammatory response

    C reactive protein will be measured

    Time frame: Day 7

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Mansilla-Rosello A, Hernandez-Magdalena J, Dominguez-Bastante M, Olmedo-Martin C, Comino-Pardo A, Escames G, Acuna-Castroviejo D. A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in surgical patients with severe sepsis admitted to the intensive care unit. J Pineal Res. 2023 Mar;74(2):e12845. doi: 10.1111/jpi.12845. Epub 2022 Dec 2. PubMed 36428216 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Aug 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Mar 31, 2026
StartEst.
Mar 26, 2026
Primary completionEst.
Aug 26, 2026
CompletionEst.
Aug 26, 2026
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07503600
Responsible party
Eman Mohamed El Mokadem (Lecturer of Pharmacy Practice and Clinical Pharmacy, Ain Shams University) — Principal investigator
First posted
Mar 31, 2026
Start date
Mar 26, 2026 (estimated)
Primary completion
Aug 26, 2026 (estimated)
Completion
Aug 26, 2026 (estimated)
Last update
Mar 31, 2026

Study contacts

Aalaa Kamal Shata, MD
Contact
aalaashata@yahoo.com
+201129214940

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Melatonin

Start the discussion